Axovant reports first clinical gene therapy data

After rebooting to focus exclusively on gene therapies, Axovant gained $0.21 (14%) to $1.69 on Monday after reporting its first data from its retooled pipeline. The lowest dose of its Parkinson's disease therapy, AXO-Lenti-PD, was safe and improved "off" symptom scores in the first two treated patients.

Axovant

Read the full 473 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE